Patrizia Pregno
Overview
Explore the profile of Patrizia Pregno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
1353
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti F, et al.
Ann Hematol
. 2023 Nov;
103(2):427-436.
PMID: 38012435
Patients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib may experience arterial occlusive events (AOEs). It is currently recommended to thoroughly assess cardiovascular risk factors before treating CML....
2.
Luciano L, Latagliata R, Gugliotta G, Annunziata M, Tiribelli M, Martino B, et al.
Ann Hematol
. 2023 Apr;
102(6):1375-1382.
PMID: 37079069
Here, we report real-world evidence on the safety and efficacy of nilotinib as a first-line treatment in elderly patients with chronic phase CML, treated in 18 Italian centers. Sixty patients...
3.
Papayannidis C, Federico V, Fianchi L, Pregno P, Pugliese N, Romano A, et al.
Mediterr J Hematol Infect Dis
. 2022 Nov;
14(1):e2022073.
PMID: 36425146
Systemic mastocytosis (SM) is a rare disease with a range of clinical presentations, and the vast majority of patients have a KIT D816V mutation that results in a gain of...
4.
Iurlo A, Cattaneo D, Artuso S, Consonni D, Abruzzese E, Binotto G, et al.
Front Oncol
. 2022 Mar;
12:839915.
PMID: 35311109
Treatment-free remission (TFR) has become a primary therapeutic goal in CML and is also considered feasible by international guidelines. TKIs dose reduction is often used in real-life practice to reduce...
5.
Giai V, Secreto C, Freilone R, Pregno P
Medicina (Kaunas)
. 2021 Oct;
57(10).
PMID: 34684081
Philadelphia negative Myeloproliferative Neoplasms (MPN) are a heterogeneous group of hematopoietic stem cell diseases. MPNs show different risk grades of thrombotic complications and acute myeloid leukemia evolution. In the last...
6.
Breccia M, Abruzzese E, Accurso V, Attolico I, Barulli S, Bergamaschi M, et al.
Br J Haematol
. 2021 Oct;
196(3):559-565.
PMID: 34636033
Limited information is available on the impact of the COVID-19 pandemic on the management of chronic myeloid leukaemia (CML). The Campus CML network collected retrospective information on 8 665 CML...
7.
Specchia G, Pregno P, Breccia M, Castagnetti F, Monagheddu C, Bonifacio M, et al.
Front Oncol
. 2021 Sep;
11:739171.
PMID: 34513714
An observational prospective study was conducted by the CML Italian network to analyze the role of baseline patient characteristics and first line treatments on overall survival and CML-related mortality in...
8.
Loscocco F, Visani G, Ruzzo A, Bagaloni I, Fuligni F, Galimberti S, et al.
Front Oncol
. 2021 May;
11:672287.
PMID: 34055641
Tyrosine kinase inhibitors (TKIs) have radically changed the outcome of chronic myeloid leukemia (CML) patients in the last 20 years. Moreover, the advent of second generation TKIs, namely nilotinib and...
9.
Breccia M, Pregno P, Castagnetti F, Bonifacio M, Tiribelli M, Gozzini A, et al.
Leukemia
. 2021 May;
35(6):1814-1816.
PMID: 34002030
No abstract available.
10.
Houshmand M, Garello F, Stefania R, Gaidano V, Cignetti A, Spinelli M, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33804056
CML is a hematopoietic stem-cell disorder emanating from breakpoint cluster region/Abelson murine leukemia 1 (BCR/ABL) translocation. Introduction of different TKIs revolutionized treatment outcome in CML patients, but CML LSCs seem...